Cardiome Pharma (CRME) Misses Q3 EPS by 10c

Cardiome Pharma (NASDAQ: CRME) reported Q3 EPS of ($0.31), $0.10 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $5 million versus the consensus estimate of $7.08 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

You May Also Be Interested In

• Wolverine World Wide (WWW) Tops Q2 EPS by 2c; offers guidance
• Compass Point Reiterates Buy Rating on WhiteFiber Inc (WYFI)
• Applied Industrial Technologies (AIT) Tops Q4 EPS by 25c, Beats on Revenue; Offers FY27 EPS Guidance